Action SLNO SOLENO THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Soleno Therapeutics, Inc.

Actions

SLNO

US8342033094

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 14/05/2024 		Varia. 5j. Varia. 1 janv.
43,5 USD +1,64% Graphique intraday de Soleno Therapeutics, Inc. -7,05% +8,07%
13/05 SOLENO THERAPEUTICS, INC. : Oppenheimer maintient sa recommandation à l'achat ZM
10/05 SOLENO THERAPEUTICS, INC. : Opinion positive de Baird ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Soleno Therapeutics Prices $138 Million Stock Offering
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Soleno Therapeutics, Inc. Announces Gwen Melincoff, Intends Not Intend to Stand for Re-Election as Director
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - April 19, 2024
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing
North American Morning Briefing : Investors -2-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Soleno Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SLNO
  4. Actualités Soleno Therapeutics, Inc.
  5. Autres langues